American Cyanamid Company

Wyeth Holdings Corporation

Wyeth

Middleton Brawner Floyd

Martin J Weiss

Robert E Schaub

John F Poletto

Karel F Bernady

William J McGahren

Hwei-Ru Tsou

Allan Wissner

Charles V Grudzinskas

Arie Zask

Semiramis Ayral-Kaloustian

Nan Zhang

Scott Christian Mayer

Dan Maarten Berger

Joshua Aaron Kaplan

Philip Frost

Xiaoxiang Liu

Kristina Martha Kutterer

Annette L Banker

Scott Mason Duncan

Bernard D Johnson

Philip Ross Hamann

Gary Harold Birnberg

Zhilian Tang

Elsebe Geraldine Overbeek-Klumpers

Ramaswamy Nilakantan

Sow-Mei Lai Chen

Tritin Tran

Marvin Reich

Miguel Angel Pagan

Mercy Adufa Otteng

Mark Ernest Salvati

Douglas B Kitchen

This invention provides compounds of Formula (I), having the structure 

[object Object]

There is provided a process for the preparation of 3-cyano-6-alkoxy-7-nitro-4-quinolone intermediates useful for the preparation of protein tyrosine kinase (PTK) inhibitors which are useful in the treatment of cancer of the formula:wherein R is alkyl(C-C) prepared by reacting a substituted anthranilate with N,N-dimethylformamide dimethyacetal to obtain a N,N-dimethylamidine which is condensed with t-butylcyanoacetate to obtain a N-(2-cyano-2-t-butoxycarbonylvinyl)anthranilate, which is hydrolyzed to yield a N-(2-cyano-2-carboxyvinyl)anthranilate followed by decarboxylating to obtain a N-(2-cyano-2-carboxyvinyl)anthranilate followed by cyclizing to obtain a 3-cyano-6-alkoxy-7-nitro-4-quinolone.

Process for the synthesis of 3-cyano-6-alkoxy-7-nitro-4-quinolones

3-cyanoquinolines as inhibitors of EGF-R and HER2 kinases

This disclosure describes certain 11-hydroxy and 11-deoxy-9-keto (or hydroxy)prostanoic acid derivatives useful as bronchodilators, anti-ulcer agents, or as intermediates.

Hydro substituted prostanoic acids and esters

This disclosure describes certain hydroxy substituted 15-deoxy-5-cis-prostenoic acids and esters useful as hypotensive agents, anti-ulcer agents, bronchodilators, anti-microbial agents, anticonvulsants, or as intermediates.

Novel 16 hydroxy 15-deoxy-5-cis-prostenoic acids and esters

This disclosure describes novel derivatives of .alpha.-(6-carboxyhexyl) furfuryl alcohol which are useful as intermediates for the preparation of natural prostaglandins and their congeners.

Derivatives of .alpha.-(6-carboxyhexyl) furfuryl alcohol

This disclosure describes novel 15-deoxy-16-hydroxy-16-substituted prostanoic acids and congeners thereof having utility as bronchodilators as hypotensive agents, and as agents for the control of excessive gastric secretion.

15-Deoxy-16-hydroxy-16-vinyl and cyclopropyl substituted prostanoic

This disclosure describes certain 15-deoxy prostanoic acid derivatives having a hydroxy group further along in the beta-chain, useful as bronchodilators, hypotensive agents, anti-ulcer agents, or as intermediates.

Derivatives of 9-hydroxy-13-trans-prostenoic acid

This disclosure describes 3-triphenylmethoxy-1-alkynes, 3-triphenylmethoxy-1-trans-alkenyl-dialkyl-alanes, and lithium 3-triphenylmethoxy-1-trans-alkenyl-dialkyl alanates useful as intermediates for the preparation of certain 11-hydroxy- and 11-deoxy-9-keto(or hydroxy)-prostanoic acid derivatives which possess bronchodilator, hypotensive, and anti-ulcer activity.

Novel 3-triphenylmethoxy-1-alkynes,

This disclosure describes homologues, analogues, congeners, and derivatives of 9-oxo-13-trans-prostenamide and of 9-hydroxy-13-trans-prostenamide, having antimicrobial activity and prostaglandin-like hypotensive activity.

Amide derivatives of 9-oxo-13-trans-prostenoic acid

This disclosure describes homologues, analogues, congeners, and derivatives of 9-oxo-13-trans-prostenoic acid and of 9-hydroxy-13-trans-prostenoic acid, having antimicrobial activity and prostaglandin-like hypotensive activity.

Derivatives of 9-oxo-13-trans-prostenoic acid esters

This disclosure describes novel 2,5-dihydro-2,5-dialkoxyfuran derivatives useful as intermediates for the preparation of the natural prostaglandins and their congeners.

2,5-Dihydro-2,5-dialkoxyfuran derivatives

This disclosure describes novel 11-deoxy-13,14-dihydro-prostaglandin-9-ketals useful as bronchodilators and as gastric acid secretion inhibitors.

16-Fluoro-11-deoxy-13-dihydro-prostaglandin

This disclosure describes 11.alpha.-homo-prostanoic acid derivatives which are useful as gastric acid secretion inhibitors.

Growing community of inventors

Suffern, NY, United States of America

Middleton Brawner Floyd